Diabetes Genetic Epidemiology and Associated Comorbidities: A Comprehensive Review


Authors : Dr. Priya Kaushik; Dr. Rashmi Nain; Dr. Rupali Bains; Dr. Prashant Kumar

Volume/Issue : Volume 9 - 2024, Issue 9 - September

Google Scholar : https://tinyurl.com/k2smpz85

Scribd : https://tinyurl.com/mrxce6kn

DOI : https://doi.org/10.38124/ijisrt/IJISRT24SEP726

PlumX Metrics

Semantic Scholar

ResearchGate

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Diabetes is characterized by elevated blood glucose levels in humans, which are mostly brought on by poor insulin production and utilization. Numerous genetic factors are responsible for causing TIDM such as PTPN22 and CTLA. People with diabetes mellitus are more likely to acquire a variety of linked conditions and conditions known as comorbidities because of a number of hereditary factors, environmental factors, certain medications, and other causes. Some of the common comorbidities that are prevalent in the T2DM patient population include congestive kidney disease, retinopathy, neuropathy, cardiovascular disease, urinary disorders, hyperlipidemia, and obesity. Diabetes has a high rate of hypertension, obesity, hyperlipidemia, and cardiovascular disease frequently coexist in patients as comorbid conditions. Knowing how genes function differs and how particular genetic factors raise the likelihood of comorbidities during diabetes can help develop effective medication for the management of diabetes Insight into how different genes operate and how specific genetic factors increase the risk of comorbidities during diabetes can aid in the development of effective diabetic medications to curb the epidemic of diabetes and its associated complications. A multifaceted approach is required, including early detection of diabetes, checking for its consequences, providing the best possible care at all levels of treatment for those who currently have the disease, and preventing diabetes in those with prediabetes. Diabetes prevalence is expected to increase, which will increase the need for rehabilitation therapy to decrease any problems the condition can cause. Exercise has been reported to improve insulin sensitivity to elevated blood sugar levels, enhance glucose absorption, decrease intra-abdominal fat a known risk factor for insulin resistance—and prevent cardiovascular issues.

Keywords : Diabetes, Epidemiology, Comorbidities, Polymorphism, Covid-19 Diabetes.

References :

  1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. Nat Rev Endocrinol [Internet]. 2011;8:228–36. Available from: http://dx.doi.org/10.1038/nrendo.2011.183
  2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF DIABETES ATLAS : Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Epub. Diabetes Res Clin Pract. ; 2022.
  3. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes : a 21st century challenge. Lancet Diabetes Endocrinol [Internet]. 2014;2:56–64. Available from: http://dx.doi.org/10.1016/S2213-8587(13)70112-8
  4. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature. 2001;414:788–91.
  5. Desisto CL, Kim SY, Sharma AJ. Prevalence Estimates o Gestational Diabetes Mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010. Prev Chronic Dis. 2014;11:1–9.
  6. Hirschhorn JN. Genetic epidemiology of type 1 diabetes. Pediatr Diabetes. 2003;4:87–100.
  7. Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochemia Medica (Zagreb). 2013;23:266–81.
  8. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes. 2001;50:S154-159.
  9. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14:619–33.
  10. Almaas E, Kovács B, Vicsek T, Oltvai ZN, Barabasi AL. Global organization of metabolic fluxes in the bacterium Escherichia coli. Barabasi, A  L. 2004;427:839–43.
  11. Barabási A lászló, Oltvai ZN. Network biology: understanding the cell’s functional organization. Nat Rev Genet. 2004;5:101–13.
  12. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabási AL. The large-scale organization of metabolic networks. Nature. 2000;407:651–4.
  13. Permutt MA. Genetic epidemiology of diabetes. Journal of Clinical Investigation. 2005;115:1431–9.
  14. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002;62:5358–64.
  15. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53:S119-124.
  16. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187–218.
  17. Sherry NA, Tsai EB, Herold KC. Natural history of beta-cell function in type 1 diabetes. Diabetes. 2005;54:S32-39.
  18. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (Banting Lecture). 2009;58:773–95.
  19. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care. 2011;34:S264-271.
  20. Vilsbøll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab. 2009;3:11–8.
  21. Hull RL, Westermark GT, Westermark PER, Kahn SE. Islet Amyloid : A Critical Entity in the Pathogenesis of Type 2 Diabetes. Journal of Clinical Endocrinol and Metabolism. 2004;89:3629–43.
  22. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91:795–826.
  23. Dunmore SJ, Brown JEP. The role of adipokines in β-cell failure of type 2 diabetes. Journal of Endocrinology. 2013;216:T37-45.
  24. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46:3–19.
  25. World Health Organization. GLOBAL REPORT ON DIABETES. 2021.
  26. Sicree R, Shaw J, Zimmet P. Prevalence and projections. In: Diabetes Atlas. In: International Diabetes Federation (3rd Edition). 3rd ed. Brussels, Belgium.: International Diabetes Federation; 2006. p. 16–104.
  27. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
  28. Qiao Q, Hu G, Tuomilehto J, Nakagami T, Balkau B, Borch-Johnsen K, et al. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care . 2003;26:1770–80.
  29. Mohan V, Ramachandran A, Snehalatha C, Mohan R, Bharani WG, Viswanathan M. High prevalence of maturity-onset diabetes of the young (MODY) among Indians. Diabetes Care. 1985;8:371–4.
  30. Popkin BM. Global nutrition dynamics : the world is shifting rapidly toward a diet linked with noncommunicable diseases. American Journal of Clinical Nutrition. 2006;84:289–98.
  31. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India : National Urban Diabetes Survey. Diabetologia. 2001;44:1094–101.
  32. Ramachandran A, Ching R, Ma W, Snehalatha C. Diabetes in Asia. The Lancet [Internet]. 2012;375:408–18. Available from: http://dx.doi.org/10.1016/S0140-6736(09)60937-5
  33. Cockram CS. The epidemiology of diabetes mellitus in the Asia-Pacific region. Hong Kong Medical Journal. 2000;6:43–52.
  34. Yoon K ho, Lee J hee, Kim J won, Cho JH, Choi Y hee, Ko S hyun, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–8.
  35. Zhai F, Wang H, Wang Z, Popkin BM, Chen C. Closing the energy gap to prevent weight gain in China. Obesity Reviews. 2008;9:107–12.
  36. Ota A, Ulrih NP. An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes. Front Pharmacol. 2017;8:1–14.
  37. AMERICAN DIABETES ASSOCIATION. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care [Internet]. 2010 [cited 2022 Dec 22];33:S62-69. Available from: care.diabetesjournals. org
  38. Pereira Rolim LCDS, Sá JR de, Chacra AR, Dib SA. Clinical Update Diabetic Cardiovascular Autonomic Neuropathy : Risk Factors , Clinical Impact and Early Diagnosis. 2007;23–31.
  39. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–60.
  40. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–97.
  41. Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA, Orchard TJ. Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. Diabetes Care. 2010;33:652–7.
  42. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430–2.
  43. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89–93.
  44. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001;60:219–27.
  45. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. British Medical Journal (BMJ). 2004;328:1105.
  46. Craig KJ, Donovan K, Munnery M, Owens DR, Williams JD, Phillips AO. Identification and management of diabetic nephropathy in the diabetes clinic. Diabetes Care. 2003;26:1806–11.
  47. Dejong RN. The nervous system complications of diabetes mellitus, with special reference to cerebrovascular changes. J Nerv Ment Dis. 1950;111:181–206.
  48. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care. 2003;26:2392–9.
  49. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–32.
  50. Andersen AR, Sandahl Christiansen J, Andersen JK, Kreiner S, Deckert T. Diabetic Nephropathy in Type 1 (Insulin-Dependent) Diabetes: An Epidemiological Study. Diabetologia. 1983;25:496–501.
  51. Wong TY, Shankar A, Klein R, Klein BEK. Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with type 1 diabetes. Diabetes. 2004;53:179–84.
  52. Ewing F, Deary IJ, Strachan MW, Frier BM. Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev. 1998;19:462–76.

Diabetes is characterized by elevated blood glucose levels in humans, which are mostly brought on by poor insulin production and utilization. Numerous genetic factors are responsible for causing TIDM such as PTPN22 and CTLA. People with diabetes mellitus are more likely to acquire a variety of linked conditions and conditions known as comorbidities because of a number of hereditary factors, environmental factors, certain medications, and other causes. Some of the common comorbidities that are prevalent in the T2DM patient population include congestive kidney disease, retinopathy, neuropathy, cardiovascular disease, urinary disorders, hyperlipidemia, and obesity. Diabetes has a high rate of hypertension, obesity, hyperlipidemia, and cardiovascular disease frequently coexist in patients as comorbid conditions. Knowing how genes function differs and how particular genetic factors raise the likelihood of comorbidities during diabetes can help develop effective medication for the management of diabetes Insight into how different genes operate and how specific genetic factors increase the risk of comorbidities during diabetes can aid in the development of effective diabetic medications to curb the epidemic of diabetes and its associated complications. A multifaceted approach is required, including early detection of diabetes, checking for its consequences, providing the best possible care at all levels of treatment for those who currently have the disease, and preventing diabetes in those with prediabetes. Diabetes prevalence is expected to increase, which will increase the need for rehabilitation therapy to decrease any problems the condition can cause. Exercise has been reported to improve insulin sensitivity to elevated blood sugar levels, enhance glucose absorption, decrease intra-abdominal fat a known risk factor for insulin resistance—and prevent cardiovascular issues.

Keywords : Diabetes, Epidemiology, Comorbidities, Polymorphism, Covid-19 Diabetes.

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe